Some patient advocacy groups opposing Medicare changes have received funding from pharma companies in the past; new techniques allow scientists to target individual cells for analysis; rural nursing homes continue to close.
Numerous patient advocacy groups recently appeared in nationwide advertisements opposing a Trump administration proposal that could limit the drugs required to be covered by Medicare. Nearly half of the groups representing patients have received payments, totaling more than $58 million in 2015 alone, from pharmaceutical companies, Kaiser Health News reported. While these groups continue to lobby Congress and the administration, experts have raised concerns regarding whether their financial ties could push them to put drugmakers’ interests ahead of the patients they represent.
Previously, studying key traits of cells required analysis of vast tissue samples, resulting in a scattered average of results from numerous cell types. Recently, scientists have discovered new techniques that allow them to directly study DNA codes, the activity of genes, and other traits of individual cells, the Associated Press reported. These methods have become widespread, revealing new details about the body and potentially allowing every human cell type to be catalogued.
Many residents have been forced to relocate as nursing homes continue to close in rural towns across the nation, mainly for financial reasons, and more individuals, swayed by changing health policies, are encouraged to live in their own homes with help from caregivers. Some residents of these nursing homes have been transferred long distances from their prior locations, making trips to visit them difficult or impossible and isolating them from spouses, friends, relatives, and religious groups they have known throughout their lives, The New York Times reported.
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
The Impact of Cost Sharing on High-Value Care
March 14th 2025Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.
Read More